This inventor holds 30 USPTO granted patents and 7 published patent applications, plus 5 CIPO patents and 7 EPO patents, primarily in Lipid Nanoparticle Formulations. Top assignees: Acuitas Therapeutics, Inc., Inex Pharmaceuticals Corporation, The University of British Columbia. Active years: 1998-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
17 out of 28 
7 out of 28 
3 out of 962 
Years Active: 1998-2026
Areas of Expertise:
Title: Steven Michial Ansell – Innovator in Lipid Nanoparticle Technology
Introduction
Steven Michial Ansell is a prominent inventor based in Vancouver, Canada, recognized for his significant contributions to the field of pharmaceuticals, particularly in lipid nanoparticle formulations. With an impressive portfolio of 26 patents, Ansell has established himself as a key figure in the development of innovative therapeutic delivery systems.
Latest Patents
Among his recent patents, one focuses on "Lipids for use in lipid nanoparticle formulations," which details compounds that aid in the delivery of therapeutic agents through lipid nanoparticles. These compounds comprise specific structures, including their pharmaceutically acceptable salts or stereoisomers. In another important patent, Ansell explores "Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids." This patent presents compounds with unique configurations that enhance the capabilities of lipid nanoparticles for efficient nucleic acid delivery.
Career Highlights
Steven Michial Ansell has lent his expertise to several leading companies in the biotechnology sector. He has worked with Acuitas Therapeutics, Inc., a firm known for its advancements in lipid nanotechnology, as well as Inex Pharmaceuticals Corporation, which is focused on innovative drug delivery solutions. His work in these organizations has been pivotal in pushing the boundaries of therapeutic applications and improving patient outcomes.
Collaborations
Throughout his career, Ansell has collaborated with distinguished professionals, including Xinyao Du and Michael J. Hope. These partnerships have fostered innovative approaches to research and development, further enhancing the efficacy of his contributions to lipid nanoparticle technologies.
Conclusion
Steven Michial Ansell’s work exemplifies the spirit of innovation in the biotechnology industry. His extensive patent portfolio and collaboration with top companies and peers underline his commitment to advancing therapeutic delivery methods, ultimately benefitting the healthcare sector and improving the lives of patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile